Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jill Gilbert

Showing results (51-60 of 78) with videos related to

Pageof 8
Sort By:
JAMA Network Open|June 6, 2024
Physician Specialty Differences in Unprofessional Behaviors Observed and Reported by CoworkersWilliam O Cooper, Gerald B Hickson, Roger R Dmochowski, et al.
Investigational New Drugs|November 18, 2016
A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancersLaura W Goff, Dana B Cardin, Jennifer G Whisenant, et al.
Oral Oncology|January 17, 2015
A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinomaJill Gilbert, Michael J Schell, Xiuhua Zhao, et al.
International Journal of Radiation Oncology, Biology, Physics|July 7, 2009
Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancerRoberto Diaz, Jerry J Jaboin, Manuel Morales-Paliza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2019
Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck CancerAthanassios Argiris, Shuli Li, Panayiotis Savvides, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 21, 2010
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patientsChristine H Chung, Erin H Seeley, Heinrich Roder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2012
Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumorsLee S Rosen, Igor Puzanov, Gregory Friberg, et al.
NPJ Precision Oncology|February 23, 2019
Genomic landscape of a metastatic malignant proliferating tricholemmal tumor and its response to PI3K inhibitionJean-Nicolas Gallant, Andrew Sewell, Karinna Almodovar, et al.
BMC Cancer|March 6, 2019
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancerJanice M Mehnert, Andrea Varga, Marcia S Brose, et al.
Plos One|September 22, 2010
Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinomaHiromitsu Hatakeyama, Haixia Cheng, Pamela Wirth, et al.
Pageof 8

Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
JAMA Network Open|June 6, 2024
Physician Specialty Differences in Unprofessional Behaviors Observed and Reported by CoworkersWilliam O Cooper, Gerald B Hickson, Roger R Dmochowski, et al.
Investigational New Drugs|November 18, 2016
A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancersLaura W Goff, Dana B Cardin, Jennifer G Whisenant, et al.
Oral Oncology|January 17, 2015
A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinomaJill Gilbert, Michael J Schell, Xiuhua Zhao, et al.
International Journal of Radiation Oncology, Biology, Physics|July 7, 2009
Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancerRoberto Diaz, Jerry J Jaboin, Manuel Morales-Paliza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2019
Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck CancerAthanassios Argiris, Shuli Li, Panayiotis Savvides, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 21, 2010
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patientsChristine H Chung, Erin H Seeley, Heinrich Roder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2012
Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumorsLee S Rosen, Igor Puzanov, Gregory Friberg, et al.
NPJ Precision Oncology|February 23, 2019
Genomic landscape of a metastatic malignant proliferating tricholemmal tumor and its response to PI3K inhibitionJean-Nicolas Gallant, Andrew Sewell, Karinna Almodovar, et al.
BMC Cancer|March 6, 2019
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancerJanice M Mehnert, Andrea Varga, Marcia S Brose, et al.
Plos One|September 22, 2010
Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinomaHiromitsu Hatakeyama, Haixia Cheng, Pamela Wirth, et al.
Pageof 8